Current Report Filing (8-k)
September 21 2017 - 3:15PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): September 21, 2017
ALDEYRA THERAPEUTICS, INC.
(Exact name of Registrant as specified in its charter)
Delaware
(State or other jurisdiction of incorporation)
|
|
|
001-36332
|
|
20-1968197
|
(Commission
File No.)
|
|
(IRS Employer
Identification No.)
|
131 Hartwell Avenue, Suite 320
Lexington, MA 02421
(Address of principal executive offices and zip code)
Registrants telephone number, including area code:
(781) 761-4904
Not Applicable
(Former
Name or Former Address, if Changed Since Last Report)
Check the appropriate box below
if the Form
8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule
14a-12
under the Exchange Act (17 CFR
240.14a-12)
|
☐
|
Pre-commencement communications pursuant to Rule
14d-2(b)
under the Exchange Act (17 CFR
240.14d-2(b))
|
☐
|
Pre-commencement communications pursuant to Rule
13e-4(c)
under the Exchange Act (17 CFR
240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this
chapter) or
Rule 12b-2
of the Securities Exchange Act of 1934
(§240.12b-2
of this chapter).
Emerging growth company ☒
If an
emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange
Act. ☒
ITEM 8.01. OTHER EVENTS.
On September 21, 2017, Aldeyra Therapeutics, Inc. (Aldeyra) announced that it completed the previously announced underwritten public offering
of its common stock. Aldeyra sold 3,967,500 shares of its common stock, including 517,500 shares sold in connection with the exercise in full by the underwriters of their option to purchase additional shares. The net proceeds of the offering,
including the exercise of the option, are approximately $26.8 million, after deducting the underwriting discounts and commissions and the estimated offering expenses payable by Aldeyra.
A copy of the press release is attached hereto as Exhibit 99.1 to this Current Report on Form
8-K
and is
incorporated herein by reference.
ITEM 9.01.
|
FINANCIAL STATEMENTS AND EXHIBITS.
|
(d) Exhibits.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on
its behalf by the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
Dated: September 21, 2017
|
|
|
|
ALDEYRA THERAPEUTICS, INC.
|
|
|
|
|
|
|
|
|
By:
|
|
/s/ Todd C. Brady, M.D., Ph.D.
|
|
|
|
|
Name:
|
|
Todd C. Brady, M.D., Ph.D.
|
|
|
|
|
Title:
|
|
President and Chief Executive Officer
|
Aldeyra Therapeutics (NASDAQ:ALDX)
Historical Stock Chart
From Apr 2024 to May 2024
Aldeyra Therapeutics (NASDAQ:ALDX)
Historical Stock Chart
From May 2023 to May 2024